In a recent market analysis, it has been projected that the anti-inflammatory drugs segment is set to witness substantial growth, exhibiting a Compound Annual Growth Rate (CAGR) of 4.6% during the forecasted period. This promising surge in the anti-inflammatory drugs segment is expected to drive the global Crohn's disease market in the coming years.
A key driving force behind this robust growth is the lack of a permanent cure for Crohn's disease, leading patients to rely on anti-inflammatory drugs for relief. The rising incidence of inflammatory bowel syndrome, including Crohn's disease and ulcerative colitis, further amplifies the demand for anti-inflammatory drugs like Prednisone, Budesonide, and Budesonide-MMX, as these drugs help manage associated conditions such as inflammation, bacterial infections, diarrhea, and mild pain.
Notable collaborations in the field include the agreement between U.S.-based Perriago Company plc and U.K.-based AstraZeneca, involving the divestment of US rights to Entocort®, a treatment for Crohn's disease. AstraZeneca's specialization in Budesonide, an anti-inflammatory drug, aligns with the growing demand for such medications.
The Asia Pacific region is also witnessing a burgeoning market for anti-inflammatory drugs, with leading companies actively raising funds for the development of cost-effective solutions.
As the global Crohn's disease market continues to evolve, the anti-inflammatory drugs segment stands poised to play a pivotal role in enhancing patient care and driving growth within the industry.
This product will be delivered within 1-3 business days.
Anti-Inflammatory Drugs: A Beacon of Hope
The anti-inflammatory drugs category has emerged as the leading sector in the global Crohn's disease market, generating a substantial increase in monetary potential between 2024 and 2031. This segment's impressive growth, with a Compound Annual Growth Rate (CAGR) of 4.2% throughout the evaluation period, is expected to establish it as the most profitable segment within the global Crohn's disease market.A key driving force behind this robust growth is the lack of a permanent cure for Crohn's disease, leading patients to rely on anti-inflammatory drugs for relief. The rising incidence of inflammatory bowel syndrome, including Crohn's disease and ulcerative colitis, further amplifies the demand for anti-inflammatory drugs like Prednisone, Budesonide, and Budesonide-MMX, as these drugs help manage associated conditions such as inflammation, bacterial infections, diarrhea, and mild pain.
Accessible Distribution Channels Fueling Growth
Manufacturers of Crohn's disease drugs are actively focusing on expanding their distribution networks through retail pharmacies and online portals. These channels provide widespread access to anti-inflammatory drugs and corticosteroids, both with and without prescriptions. Additionally, consumers can take advantage of discounts on bulk purchases through online platforms, enhancing the segment's growth.Challenges Ahead
Despite the promising growth prospects, challenges persist. In regions like Africa and Nigeria, the low diagnosis rate of inflammatory bowel syndrome and a casual attitude towards treatment duration hinder revenue growth in the anti-inflammatory drugs segment. Moreover, in countries like India and China, some Crohn's disease patients are turning to alternative treatment options such as Ayurveda and Homeopathy, posing a potential hindrance to the segment's progress.Regional Markets and Collaborations
In North America, the anti-inflammatory drugs segment is expected to be the most lucrative, with the U.S. serving as the largest Crohn's disease market in the region. North America is projected to register a CAGR of 4.3%, closely followed by Europe with a 4.0% Compound Annual Growth Rate in this segment.Notable collaborations in the field include the agreement between U.S.-based Perriago Company plc and U.K.-based AstraZeneca, involving the divestment of US rights to Entocort®, a treatment for Crohn's disease. AstraZeneca's specialization in Budesonide, an anti-inflammatory drug, aligns with the growing demand for such medications.
The Asia Pacific region is also witnessing a burgeoning market for anti-inflammatory drugs, with leading companies actively raising funds for the development of cost-effective solutions.
As the global Crohn's disease market continues to evolve, the anti-inflammatory drugs segment stands poised to play a pivotal role in enhancing patient care and driving growth within the industry.
Competitive Analysis:
Some of the prominent players in the global market for Crohn's disease treatment are:- Abbvie Inc.
- Celgene Corporation
- Genetech
- Johnson & Johnson
- Pfizer Inc.
- Prometheus Laboratories Inc. (Nestle)
- Salix Pharmaceuticals Inc.
- Takeda's Pharmaceutical Ltd
- Janssen Pharmaceuticals
- Biogen
- AstraZeneca
Market segmentation
By Drug Type
- Anti-inflammatory drugs
- Immune system suppressors
- Antibiotics
- Biologics
- Anti-diarrheal
- Pain relievers
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- MEA
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Market Overview
3. Global Crohn’s Disease Treatment Market Outlook, 2018 - 2031
4. North America Crohn’s Disease Treatment Market Outlook, 2018 - 2031
5. Europe Crohn’s Disease Treatment Market Outlook, 2018 - 2031
6. Asia Pacific Crohn’s Disease Treatment Market Outlook, 2018 - 2031
7. Latin America Crohn’s Disease Treatment Market Outlook, 2018 - 2031
8. Middle East & Africa Crohn’s Disease Treatment Market Outlook, 2018 - 2031
9. Competitive Landscape
10. Appendix
Companies Mentioned
- Allergan, Inc.
- UCB S.A.
- AbbVie Inc.
- Perrigo Company plc
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson Services, Inc.
- Bayer AG
- Ferring B.V.
